logo-loader

Numinus Wellness teams with KGK Science for clinical trial of Natural Psilocybin Mushroom Extract

Last updated: 12:37 28 Apr 2021 EDT, First published: 12:50 28 Apr 2021 EDT

Numinus Wellness (CVE: NUMI) CEO Payton Nyquvest joined Steve Darling from Proactive to share news the company has formed a partnership with KGK Science to undertake a new Psilocybin extraction clinical trial.

Nyquvest telling Proactive Phase 1 of the trial will enroll 14 human volunteers and assess the safety and psychoactive properties of a Psilocybe mushroom product. That extract will be formulated at the Numinus Bioscience lab in British Columbia, Canada.

Nyquvest also saying this landmark trial would result in safety and efficacy data for a natural Psilocybin product which could subsequently be used for further research and government-approved special access or compassionate access programs.

Proactive research analyst on Numinus Wellness' annual results

Proactive research analyst Daniel Appiah talks to Thomas Warner about his report on Numinus Wellness Inc. (TSX:NUMI, OTC:LKYSF), published to coincide with the release of the company's annual results. Appiah gives his take on how the company is currently performing and looks ahead to what its...

on 12/16/2022